Vincent Dore
@vincentDore2
Followers
148
Following
65
Media
2
Statuses
79
Senior neuroimaging scientist @CSIRO and @RoweLab_aus
Joined January 2021
🧪 Les biomarqueurs sont de véritables indices biologiques. Dans la maladie d’Alzheimer, ils permettent de : 🔍 Détecter très tôt la maladie 🧠 Mieux poser le diagnostic 💊 Suivre l’efficacité des traitements 📘 Découvrez notre carrousel de la semaine : https://t.co/NEEntY36BF
0
1
0
After more than 3 years of work, visualizing over 6,500 tau PET scans, and countless manuscript revisions, I still have to blink twice to believe it: our paper “Frequency and Clinical Outcomes Associated With Tau PET Positivity” is now published in JAMA. https://t.co/8iGcly62Qe
jamanetwork.com
This study used pooled data to estimate the frequency of tau positron emission tomography positivity and its associated risk of clinical outcomes.
1
14
34
🚨Donanemab has been approved for use in Aus. ADNeT Director Prof Chris Rowe said "Today is a momentous day in the treatment of the most common form of dementia. We must now ensure our health system is ready to bring these new treatments to patients" More➡️ https://t.co/U9VuFyHtxs
0
4
9
🚨Donanemab has been approved for use in Aus. ADNeT Director Prof Chris Rowe said "Today is a momentous day in the treatment of the most common form of dementia. We must now ensure our health system is ready to bring these new treatments to patients" More➡️ https://t.co/Wm6vFWORYG
0
3
8
https://t.co/5E0UNhC0n3 Finally, some much-needed progress! The TGA in Australia has approved Donanemab for early symptomatic Alzheimer's disease. This offers new hope by slowing cognitive and functional decline. Every step counts! #AlzheimersTreatment #Dementia #Australia
abc.net.au
The TGA has approved a drug found to slow the cognitive decline associated with Alzheimer's disease but it will only be available for a select few who can afford it privately.
0
1
4
Australians are travelling overseas for dementia treatments like lecanemab after TGA rejection. ADNeT urges approval so that the 433k Australians living with dementia can access the latest treatments at home. #DementiaTreatment #ADNeT @AlzDisInt
We are running a mini campaign to highlight how access to new treatments for #alzheimers is forcing people - those who can afford it- to travel for them. Below -in the replies- quotes from medical professionals and people travelling - if you have a story please share it with us
3
3
2
Approved in Europe the first disease-modifying treatment for #Alzheimer's disease. Great news for patients, families and all of us interested in this devastating disease.
📢The CHMP recommends authorising a new treatment for early #AlzheimersDisease in the EU. Leqembi is intended for treatment of mild dementia and cognitive impairment in a restricted patient population with a specific genetic make-up. 👉 https://t.co/0rUpn7K7ri
0
7
25
Exciting news! Our findings on the Lumipulse #pTau217 assay were featured in @theheraldsun and @dailytelegraph. In this interview, Prof. Christopher Rowe explains the difference this blood test could make for #Alzheimers diagnosis. Have a read here:
Pleased to present our paper @eBioMedicine, on the Lumipulse plasma pTau217 assay. Lumipulse-G platform → large global installation base in clinical pathology services → better access/uptake of plasma #ptau217 into clinical practice. Link: https://t.co/dZaIRfJPL2
#Alzheimers
0
1
8
Tau PET GWAS turns up potential new #alzheimersdisease gene. The oxidizing enzyme CYP1B1 associates with higher tangle load. @IUMedSchool
0
3
17
Association of in vivo retention of Flortaucipir PET with tau neuropathology in corresponding brain regions Check out our most recent publication, led by @to_freiburghaus & @DW_Pawlik at Acta Neuropathologica. Main findings: 1⃣ Flortaucipir PET signal primarily reflects tau
1
8
30
🚨🚨 Paper alert 🚨 🚨 I am honored to have been part of this article led by @LarsRaket. The article provides very important estimations of scenarios for the long-term effect of amyloid-targeting therapies! Also, with @_michael_scholl @AlexisMoscoso9
https://t.co/l6QlnVDsdK
alz-journals.onlinelibrary.wiley.com
INTRODUCTION Recent clinical trials of amyloid beta (Aβ)-targeting therapies in Alzheimer's disease (AD) have demonstrated a clinical benefit over 18 months, but their long-term impact on disease...
0
8
23
🚨 NEW PREPRINT! "Prediction of future cognitive decline among cognitively unimpaired individuals using measures of soluble phosphorylated tau or tau tangle pathology" I am very pleased to present our most recent work! It concerns a large multi-cohort study in which we
1
21
69
Latest article from our team in @CPH_ECU led by #NHMRC Emerging Fellow Dr Emmanuel Adewuyi (@thepurposedrive). A deep dive into the shared #genetics of type-2 #diabetes & #Gut disorders. @EdithCowanUni @TeniellePorter @eleanorkobrien
#statisticalgenetics #MR
A large-scale analysis of genome-wide association studies links type 2 diabetes with gastrointestinal disorders, implicating causal associations, shared genes and biological pathways. https://t.co/g0ryts0TBU
1
2
10
Not long to go now! Don't forget to register for this unique opportunity to meet Prof Lautenschlager and likeminded researchers in #Neuroscience #Alzheimers hosted by @DrKaramacoska and @ISTAART
0
1
0
Is there clinical evidence for the use of GLP-1 receptor agonists in #Alzheimers disease? Our recent systematic review suggests current data is limited, but upcoming RCT's may yield more insights: https://t.co/xXmCYxTxtn
#ADresearch @vincentDore2 @RoweLab_aus
journals.sagepub.com
Background: Alzheimer’s disease (AD) is the most common cause of dementia. While preclinical studies have shown benefits of glucagon-like peptide 1 receptor ago...
0
2
7
Are ice cream sales a useful predictor of swimming pool deaths, over and above daily temperature? 🍦🏊♂️ One of the statistical papers every PhD student should read! 📊 #Statistics #PhD #Research
journals.plos.org
Social scientists often seek to demonstrate that a construct has incremental validity over and above other related constructs. However, these claims are typically supported by measurement-level...
0
0
5
Don't miss out on the opportunity to join our team! The final day (21st) to apply for this postdoc position is fast approaching. #AlzheimersDisease #NeuroImaging #BrainScience #AlzheimerResearch #Neuroscience #ClinicalTrials #jobopening #careerdevelopment
🌊🏄♀️ Exciting news! A postdoctoral opportunity is now available in my team in Melbourne! Join us and contribute to cutting-edge research in imaging the aging brain. #postdocopportunity #scienceAustralia 🏖️🐨🦘 https://t.co/OltJIZdnqT
0
5
9
🌊🏄♀️ Exciting news! A postdoctoral opportunity is now available in my team in Melbourne! Join us and contribute to cutting-edge research in imaging the aging brain. #postdocopportunity #scienceAustralia 🏖️🐨🦘 https://t.co/OltJIZdnqT
jobs.csiro.au
CSIRO Postdoctoral Fellowship in PET Neuroimaging for Alzheimer's Disease
2
8
12
Out now in @TheLancetNeuro A comparison of tau PET pathology in Down Syndrome (DS) and Autosomal Dominant Alzheimer Disease (ADAD). https://t.co/0au7NKqkt2
4
25
80
New EJNMMI paper, showing that tau deposition is related to dopamine difficiency in 4R tauopathies by combining PI-2620 tau-PET and DaT-SPECT. As always, great collaboration and congrats to @matbrendel, @GunterHoglinger and the entire LMU Neurodeg team https://t.co/g4NhXgaYlf
link.springer.com
European Journal of Nuclear Medicine and Molecular Imaging - We hypothesized that severe tau burden in brain regions involved in direct or indirect pathways of the basal ganglia correlate with more...
1
6
23